Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists devise new way to generate canine stem cells
The iPSCs were generated without feeder cells, a process which had not been possible before.
The method reprograms the cells from urine samples.

Researchers have discovered a method to generate canine induced pluripotent stem cells (iPSCs) from urine samples.

The findings could bring companion animal medicine research a step closer to veterinary regenerative treatment.

The research, conducted by scientists at Osaka Metropolitan University, aimed to discover how iPSCs could be used in the study of veterinary regenerative medicine, as well as contributing to new discoveries in human regenerative medicine.

However, canine somatic cells have a much lower reprogramming efficiency than those of humans. This means that there are fewer types of canine cells which can be used to generate iPSCs.

The induction of iPSCs would often use feeder cells from a different species, although it is considered safer to minimise the use of xenogeneic components. Therefore, scientists were keen to find a method of reprogramming various canine cells in dogs without using feeder cells.

The research team were able to identify six reprogramming genes, which could increase canine iPSC generation by 120 times compared to conventional methods using fibroblasts.

Using these genes, the scientists were able to create iPSCs by reprogramming stem cells from canine urine samples. This was a non-invasive, painless and straight-forward method.

Not only were the scientists able to create the cells with reduced xenogeneic components, the iPSCs were also generated without feeder cells, a process which had not been possible before.

It is believed that this discovery could not only further studies of veterinary regenerative medicines, but also lead to new discoveries in human regenerative medicines.

Prof Shingo Hatoya, from the Graduate School of Veterinary Science at Osaka Metropolitan University, led the research team. They said: "As a veterinarian, I have examined and treated many animals,

"However, there are still many diseases that either cannot be cured or have not been fully understood. In the future, I am committed to continue my research on differentiating canine iPSCs into various types of cells and applying them to treat sick dogs, hopefully bringing joy to many animals and their owners."

The full study can be found in the journal Stem Cell Reports.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.